Luma closes $410M fund with a longer bet on biotech
LumaBio Fund I has closed at $410M with a 15-year structure designed to better match the long development cycles of life sciences companies.
Biotech companies often need more time than a conventional venture fund is designed to give them. Luma is building that longer horizon directly into its fund structure.
What happened
Luma Group closed LumaBio Fund I at $410 million, its inaugural life-sciences venture fund. The investor base includes financial institutions, sovereign wealth funds, insurers, family offices and ultra-high-net-worth investors. The vehicle is structured with a 15-year life and has already invested in more than 10 biotech companies.
Why it matters
Drug development can take many years across discovery, clinical trials and regulatory approval. A longer fund life gives an investor more flexibility to support companies through those milestones rather than being forced toward an exit by a conventional fund clock.
The bigger picture
As biotech becomes more capital intensive, fund structure itself can become a competitive advantage. Investors with patient capital may be better positioned to back companies through the full scientific and clinical cycle.